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Abstract
Rationale—Alcohol and nicotine co-use can reciprocally promote self-administration and drug-
craving/drug-seeking behaviors. To date, the neurocircuitry in which nicotine influences ethanol 
(EtOH) seeking has not been elucidated. Clinical and preclinical research has suggested that the 
activation of the mesolimbic dopamine system is involved in the promotion of drug seeking. 
Alcohol, nicotine, and serotonin-3 (5-HT3) receptors interact within the posterior ventral 
tegmental area (pVTA) to regulate drug reward. Recently, our laboratory has reported that 
systemic administration of nicotine can promote context-induced EtOH seeking.
Objectives—The goals of the current study were to (1) determine if microinjections of 
pharmacologically relevant levels of nicotine into the pVTA would enhance EtOH seeking, (2) 
determine if coadministration of nicotinic cholinergic receptor antagonist (nACh) or 5-HT3 
receptor antagonists would block the ability of nicotine microinjected into the pVTA to promote 
EtOH seeking, and (3) determine if 5-HT3 receptors in the pVTA can modulate EtOH seeking.
Results—Nicotine (100 and 200 µM) microinjected into the pVTA enhanced EtOH seeking. 
Coinfusion with 200 µM mecamylamine (nACh antagonist) or 100 and 200 µM zacopride (5-HT3 
receptor antagonist) blocked the observed nicotine enhancement of EtOH seeking. The data also 
indicated that microinjection of 1 µM CPBG (5-HT3 receptor agonist) promotes context-induced 
EtOH seeking; conversely microinjection of 100 and 200 µM zacopride alone reduced context-
induced EtOH seeking.
Conclusions—Overall, the results show that nicotine-enhanced EtOH-seeking behavior is 
modulated by 5-HT3 and nACh receptors within the pVTA and that the 5-HT3 receptor system 
within pVTA may be a potential pharmacological target to inhibit EtOH-seeking behaviors.
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Introduction
Alcohol and nicotine are also commonly used together, and the co-abuse of both drugs can 
increase use and relapse more than either drug alone. The severity of nicotine dependency is 
linked to more severe levels of alcohol relapse (Abrams et al. 1992; Gulliver et al. 1995) and 
impairs the likelihood that an individual with alcohol dependence will succeed in becoming 
abstinent if they continue to smoke during this period (Gulliver et al. 1995; Sobell et al. 
1995; Daeppen et al. 2000). Preclinical studies have provided evidence that nicotine can 
enhance relapse behaviors, such as ethanol (EtOH) seeking (Le et al. 2003; Hauser et al. 
2012a) and EtOH relapse drinking (Lopez-Moreno et al. 2004; Alen et al. 2009; Hauser et 
al. 2012a).
The activation of dopamine (DA) neurons in the ventral tegmental area (VTA) plays a 
critical role in drug reward/reinforcement and compulsive drug-seeking behaviors; both 
EtOH (Brodie et al. 1990; Brodie et al. 1999) and nicotine (Calabresi et al. 1989; Nisell et al. 
1994) can activate VTADA neurons. Nicotinic acetylcholine (nACh) receptors within the 
VTA are thought to be one of the molecular targets underlying EtOH and nicotine co-abuse. 
The reinforcing effects of nicotine are modulated via stimulation of nACh receptors within 
the VTA (Corrigall et al. 1994; Nisell et al. 1994); studies have shown that the reinforcing 
effects of EtOH may be partially modulated by nACh receptors (Blomqvist et al. 1996; 
Ericson et al. 2003; Soderpalm et al. 2000). EtOH intake (Le et al. 2000; Hendrickson et al. 
2009) and nicotine-stimulated EtOH drinking (Smith et al. 1999; Sajja and Rahman 2012) 
can be reduced by mecamylamine (Mec), a nonselective nACh receptor antagonist.
A few studies have examined the involvement of nACh receptors in EtOH-seeking behavior. 
Local infusion of α-conotoxin MII (α3β2, β3, and α6 nicotinic antagonists) into the VTA 
and systemic administration of Mec can reduce cue-induced EtOH seeking, whereas 
dihydro-β-erythroidine (α4β2 nicotinic antagonist) did not have an effect (Lof et al. 2007). 
In addition, varenicline, an α4β2 nicotinic receptor partial agonist, reduced EtOH-seeking 
behavior (Steensland et al. 2007).
The nACh and serotonin-3 (5-HT3) receptors are members of the Cys-loop ligand-gated ion 
channel superfamily; 5-HT3 receptors share up to 30 % sequence homology of nACh 
receptors. Nicotine binds with a higher affinity to the 5-HT3 receptor compared to any nACh 
receptor (Jackson and Yakel 1995; Breitinger et al. 2001; Gurley and Lanthorn 1998). In 
addition, the nACh receptor antagonist Mec and epibatidine (nicotinic agonist) have at least 
a fourfold greater affinity for the 5-HT3 receptor than the nACh receptor (Drisdel et al. 
2008). In contrast, zacopride (Zac), a 5-HT3 receptor antagonist, does not have an 
appreciable affinity for nicotinic receptors (Kidd et al. 1993).
The posterior VTA (pVTA) mediates the reinforcing actions of EtOH (Rodd-Henricks et al. 
2000) and nicotine (Ikemoto et al. 2006; Hauser et al. 2013). The activation of 5-HT3 
receptors is involved in mediating the reinforcing effects of EtOH (Rodd-Henricks et al. 
2003) and nicotine (Hauser et al. 2013) within the pVTA. The pVTA is also involved in 
mediating context-induced EtOH-seeking behavior via activation of local DA neurons 
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(Hauser et al. 2011). Because of the similarities in structure between nACh and 5-HT3 
receptors (Mascia et al. 2000; Peters et al. 2006), and the potential interactions of these 
receptors and of nicotine at the 5-HT3 receptor (Bianchi et al. 1995; Gurley and Lanthorn 
1998; Nayak et al. 2000; Dougherty and Nichols 2009), it is possible that some of the effects 
of nicotine on EtOH seeking within the pVTA may be mediated in part through activation of 
5-HT3 receptors.
The selectively bred alcohol-preferring (P) line of rats appears to be a useful animal model 
to study EtOH and nicotine use. P rats will intravenously (i.v.) self-administer more nicotine 
as well as express greater nicotine-seeking behavior than the alcohol-nonpreferring (NP) rats 
(Le et al. 2006a). Nicotine also has greater reinforcing effects in P than NP rats (Le at al. 
2006a). Intracranial self-administration studies have provided further support that EtOH and 
nicotine may share common genetic risk factors because P rats are more sensitive to the 
reinforcing effects of EtOH (Rodd et al. 2003) and nicotine (Hauser et al. 2013) within the 
pVTA compared to Wistar rats.
Context has been shown to influence extinction learning and reinstatement of previously 
learned behaviors (Bouton 2002). In a spontaneous recovery paradigm, subjects are allowed 
to self-administer in a specific environment, the behavior is extinguished in the same 
environment, the subjects are withheld from that environment for a certain time, and 
behavior is recorded when the animals are returned to the original environment. Since 
spontaneous recovery is defined in the alcohol clinical literature as the cessation of alcohol 
consumption in human alcoholics without treatment intervention, we have altered the term 
to Pavlovian Spontaneous Recovery (PSR). PSR is a unique phenomenon in that it is time 
dependent (Bouton 1988), directly correlated to reward saliency (Robbins 1990), and 
contextual cues associated with first-learned signals and the amount of first- and second-
learned associations (Brooks 2000).
The objectives of the current study were to test the hypothesis that local application of 
nicotine within the pVTA would enhance context-induced EtOH-seeking behavior and that 
nicotine’s stimulating effects are mediated in part via activation of 5-HT3 and nACh 
receptors in the pVTA. In addition, we tested the hypothesis that the activation of 5-HT3 
receptors alone in the pVTA is involved in mediating context-induced EtOH-seeking 
behavior.
Methods
Animals
Adult EtOH-naïve female P rats from the 70th generation weighing 250–325 g at the start of 
the experiment were used. Female rats were used in the present study because they maintain 
their body and head size better than male rats for more accurate and reliable stereotaxic 
placements. Rats were maintained on a 12-h reversed light dark cycle (lights off at 0900 
hours). Food and water were available in the home cage ad libitum throughout the 
experiment. All research protocols were approved by the institutional animal care and use 
committee and are in accordance with the guidelines of the Institutional Care and Use 
Committee of the National Institute on Drug Abuse, National Institutes of Health, and the 
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Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal 
Resources, Commission on Life Sciences, National Research Council 1996).
Chemical agents and vehicle
Nicotine HCl (Sigma, St. Louis, MO), Mec (Sigma, St. Louis, MO), Zac (Tocris Bioscience, 
Ellisville, MO), and 1-(m-chlorophenyl)-biguanide (CPBG, Tocris Bioscience, Ellisville, 
MO) were dissolved in artificial cerebrospinal fluid (aCSF), and the pH was adjusted to 
7.4±0.1. The aCSF consisted of (in millimolar) 120.0 NaCl, 4.8 KCl, 1.2 KH2PO4, 1.2 
MgSO4, 25.0 NaHCO3, 2.5 CaCl2, and 10.0 D-glucose.
Operant response training
P rats were placed in the standard two-lever operant-conditioning chamber, as previously 
described (Rodd-Henricks et al. 2002a, b; Rodd et al. 2006; Hauser et al. 2011, 2012a). 
Operant-conditioning sessions were 60 min in duration and occurred daily for 10 weeks. The 
EtOH concentration used during self-administration was 15% (v/v). During the initial 4 
weeks of daily access to operant responding, both solutions (water and EtOH) were 
reinforced on a fixed ratio 1 (FR1) schedule. The response requirement for EtOH was 
increased to FR3 for 3 weeks, and then to FR5 for 3 weeks. After the P rats had established 
stable levels of responding on the FR5 schedule for EtOH and FR1 for water, they 
underwent seven sessions of extinction training (60 min/session), when neither water nor 
EtOH was available.
Stereotaxic surgeries
After extinction training, all rats were maintained in the home cages for 14 days. Previous 
research has shown that 2 weeks of home caging produced robust expression of EtOH 
seeking (Rodd-Henricks et al. 2002a, b; Rodd et al. 2006). Stereotaxic implantation was 
performed after 7 days in the home cage. While under isoflurane anesthesia, rats were 
prepared for bilateral stereotaxic implantation of 22-gauge guide cannula (Plastics One, 
Roanoke, VA) into the pVTA; the guide cannula was aimed 1.0 mm above the target region. 
Coordinates (Paxinos and Watson 1998) for placements to target the pVTA were −5.8 mm 
posterior to bregma, +2.1 mm lateral to the midline, and −8.5 mm ventral from the surface 
of the skull at a 10° angle to the vertical. A 28-gauge stylet was placed into the guide 
cannula and extended 0.5 mm beyond the tip of the guide. After surgery, rats were 
individually housed and allowed to recover for 7 days. Animals were handled for at least 5 
min daily beginning on the fourth recovery day and were habituated for 2 consecutive days 
to the handling procedures necessary for microinjections.
Context-induced EtOH seeking: Pavlovian Spontaneous Recovery (PSR) testing
After 14 days in the home cages, rats were returned to the operant chambers for PSR testing 
in 60-min sessions. The FR5-FR1 schedule lever contingencies and dipper functioning were 
maintained, but EtOH and water were absent for the four consecutive PSR sessions (Hauser 
et al. 2012a; Rodd et al. 2006). There are four consecutive PSR sessions because previous 
studies have shown that exposure to EtOH odor cues or EtOH priming (Rodd-Henricks et al. 
Hauser et al. Page 4
Psychopharmacology (Berl). Author manuscript; available in PMC 2015 July 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2002a, b) and some drugs (Dhaher et al. 2010) may enhance PSR responding for more than 
one session.
Experiment 1: effects of nicotine in the pVTA on EtOH seeking—The first set of 
rats was microinjected bilaterally with vehicle (aCSF) or nicotine (50, 100, or 200 µM, n=7–
8/group). Nicotine was administered using the electrolytic microinfusion transducer system, 
as previously described (Hauser et al. 2011). Nicotine was administered consecutively to 
both sides of the pVTA for 10 min/side using three 5-s pulses per minute; each 5-sec pulse 
infused 100 nl. These concentrations of nicotine have been previously shown to be self-
infused into the pVTA (Hauser et al. 2013). In this and all subsequent experiments, the 
micro-injections were given prior to only the first PSR session, starting 25–30 min before 
the session. The use of the electrolytic microinfusion transducer system has been shown to 
give good neuroanatomical specificity (Ikemoto et al. 2006; Rodd-Henricks et al. 2000, 
2002a; Rodd et al. 2007).
Experiment 2: coinfusion of nicotine with Mec into the pVTA on EtOH seeking
—The second set of rats was microinjected bilaterally with vehicle (aCSF), 100 µM nicotine
+100 µMMec, or 100 µM nicotine+200 µMMec (n=6–7/group). The 100-µM nicotine data 
from experiment 1 were used to compare the effects of Mec+nicotine. The concentrations of 
Mec used have been reported to effectively reduce EtOH drinking (Ericson et al. 1998) and 
EtOH-associated cue-induced DA levels within the VTA (Lof et al. 2007).
Experiment 3: coinfusion of nicotine with Zac into the pVTA on EtOH seeking
—The third set of rats was microinjected bilaterally with vehicle (aCSF), 100 µM nicotine
+100 µM Zac, 100 µM nicotine+ 200 µM Zac (n=5–7/group). The 100-µM nicotine data 
from experiment 1 were used to compare the effects of Zac+nicotine. These concentrations 
of Zac were previously used in intracranial self-administration (ICSA) studies to inhibit the 
self-infusion of EtOH into the pVTA (Rodd-Henricks et al. 2003).
Experiment 4: effects of Zac in the pVTA on EtOH seeking—The fourth set of rats 
(n=5–8/group) was microinjected bilaterally with aCSF, or 100 or 200 µM Zac.
Experiment 5: effects of CPBG in the pVTA on EtOH seeking—The fifth set of 
rats (n=4–5/group) was microinjected bilaterally with aCSF, or 1 or 10 µM CPBG. The 
concentrations of CPBG were selected based on previous research that showed P rats will 
self-administer 1 and 10 µM CPBG into the pVTA (Rodd et al. 2007).
Histology
At the termination of the experiment, 1 % bromophenol blue (0.5 µl) was injected into the 
infusion site. Subsequently, the animals were given a fatal dose of pentobarbital and then 
decapitated. The brains were removed and immediately frozen at −70 °C. The frozen brains 
were subsequently equilibrated at −15 °C in a cryostat microtome and then sliced into 40-µm 
sections. Sections were then stained with cresyl violet and examined under a light 
microscope for verification of the injection site using the rat brain atlas of Paxinos and 
Watson (1998).
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Statistical analysis
Overall operant responding (60 min) data were analyzed with a mixed factorial ANOVA 
with a between-subjects factor of dose and a repeated measure of “session”. For the PSR 
tests, the baseline measure for the factor of session was the average number of responses on 
the EtOH or water lever for the last three extinction sessions. Post hoc Tukey’s b was used 
to determine individual differences. All analyses with p≤0.05 were considered significant.
Results
Histology placements
The pVTA is defined as the VTA region at the level of the interpeduncular nucleus at 5.4–
6.0 mm posterior to bregma (Rodd-Henricks et al. 2000). Only animals that had correct 
injector placements were used in data analysis. As seen in Fig. 1, the pVTA injector 
placements were at 5.4–6.0 mm posterior to bregma. The success rate for dual pVTA 
placements was around 85 %. Incorrect injection sites were located in the anterior VTA or 
red nucleus.
Responses on the EtOH and water levers during self-administration and extinction
Average responses on the EtOH lever during the last five sessions of the EtOH self-
administration part of the procedure ranged from 168 to 218 responses/session across the 
five experiments (Table 1). Average responses on the water lever during these sessions were 
usually less than 20 responses/session. Average EtOH intakes during these five sessions 
ranged from 1.2 to 1.5 g/kg/session. Responses on the EtOH lever were markedly reduced 
across extinction sessions, whereas the low responses on the water lever were not 
significantly altered across extinction sessions (Table 1).
Effects of nicotine in the pVTA on EtOH seeking
Examining the effects of nicotine alone on the number of responses on the lever previously 
associated with the delivery of EtOH (Fig. 2a) indicated a significant effect of session 
(F4,13=30.10, p<0.001), “dose” (F3,16=13.98, p<0.001), and session by dose interaction 
(F12,45=3.18, p<0.01). Post hoc comparisons indicated that P rats given 100 or 200 µM 
nicotine directly into the pVTA responded more than P rats microinjected with aCSF or 50 
µM nicotine during the first PSR session. Comparison to extinction baseline values revealed 
that responding on the lever previously associated with EtOH was significantly increased 
during the first PSR session for rats given aCSF or 50,100, or 200 µMnicotine (p values 
<0.05). Nicotine did not significantly alter responses on the lever previously associated with 
water (Fig. 2b).
Microinjection of nicotine into areas outside of the pVTA (i.e., the anterior VTA and red 
nucleus) did not appear to significantly alter responses on the EtOH or water levers during 
the first or subsequent PSR sessions (Fig. 3).
Effects of co-infusion of nicotine with Mec into the pVTA on EtOH-seeking
The number of responses on the lever previously associated with the delivery of EtOH for 
rats given aCSF, 100 µM nicotine, or 100 µM nicotine with Mec (Fig. 4a) indicated a 
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significant effect of session (F4,14=25.19, p<0.001), dose (F3,16= 7.08, p<0.01), and session 
by dose interaction (F12,45=2.71, p<0.01). Post hoc comparisons indicated that P rats given 
100 µM nicotine+200 µMMec responded significantly less than P rats microinjected with 
100 µMnicotine, 100 µM nicotine+100 µMMec, or aCSF. P rats given 100 µM nicotine or 
100 µMnicotine+100 µM Mec responded more on the EtOH lever during the first PSR 
session compared to the aCSF group. Comparison to extinction baseline values indicated 
responding on the lever previously associated with EtOH was significantly increased during 
the first PSR testing for rats given aCSF, 100 µM nicotine and 100 µM nicotine+100 
µMMec (p values<0.05). There were no significances in the number of responses on the 
lever previously associated with the delivery of water during the first PSR session (Fig. 4b).
Effects of coinfusions of nicotine with Zac into the pVTA on EtOH seeking
Analysis of the number of responses on the lever previously associated with the delivery of 
EtOH for rats microinjected with aCSF, 100 µM nicotine, 100 µMnicotine+100 µM Zac, or 
100 µM nicotine+200 µM Zac (Fig. 5a) indicated a significant effect of session (F4,15= 
11.790, p<0.001), dose (F3,18=6.975, p<0.01), and session by dose interaction 
(F12,51=2.788,p<0.005). Post hoc comparisons indicated that P rats given 100 µMnicotine 
+100 or 200 µM Zac responded significantly less than P rats given aCSF or nicotine alone. P 
rats given 100 µM nicotine responded more during the first PSR session compared to the 
aCSF group. P rats given aCSF or nicotine alone responded more during the first PSR 
session compared to extinction baseline (p value <0.01). Microinjection of 100 µM nicotine
+100 µM Zac (but not nicotine+ 200 µM Zac) reduced the number of EtOH lever responses 
during the first PSR session compared to extinction baseline (p values <0.01). The results 
indicated that there were no significant group differences for the number of responses on the 
lever previously associated with water (Fig. 5b).
Effects of Zac in the pVTA on EtOH-seeking
For Zac alone, the number of responses on the lever previously associated with the delivery 
of EtOH (Fig. 6a) indicated a significant effect of session (F4,12= 17.69, p<0.001), dose 
(F2,15=3.70, p=0.049), and session by dose interaction (F8,26=4.47,p<0.01). Post hoc 
comparisons indicated that P rats given 100 and 200 µM Zac responded significantly less 
than P rats given aCSF. Comparison to extinction baseline values revealed that responding 
on the lever previously associated with EtOH was significantly increased during the first 
PSR testing for rats that administered aCSF (p<0.01), where-as there were no differences 
between 100 or 200 µM Zac compared to extinction baseline. There were no significant 
group differences in the number of responses on the lever previously associated with water 
during the first PSR session (Fig. 6b).
Effects of CPBG in the pVTA on EtOH seeking
For CPBG, examining the number of responses on the lever previously associated with the 
delivery of EtOH (Fig. 7a) indicated a significant effect of session (F4,6 = 42.99, p<0.001), 
dose (F2,9=4.07, p=0.055), and session by dose interaction (F8,12=6.78, p<0.01). Individual 
ANOVAs performed for each session indicated a significant effect of dose during the first 
PSR test session (F2,9=68.40,p<0.001). Post hoc comparisons indicated that P rats given 1 
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µM CPBG directly into the pVTA responded significantly more during the first PSR session 
than P rats given aCSF, whereas those that administered 10 µM CPBG responded 
significantly less during the first PSR compared to the aCSF group. In addition, EtOH lever 
responses were higher in the aCSF and 1-µM CPBG groups during the first PSR test session 
compared to extinction baseline (p values <0.05). There were no significant differences 
between 10-µM CPBG and extinction baseline values. There were no significant group 
differences in the number of responses on the lever associated with water during the first 
PSR session (Fig. 7b).
Discussion
The major findings of this study are that physiologically relevant levels of nicotine 
microinjected into the pVTA can promote context-induced EtOH seeking and that 5-HT3 
and nACh receptors are involved. The 5-HT3 receptor antagonist Zac microinjected into the 
pVTA reduced responding on the EtOH lever in PSR test at both doses (Fig. 6a), suggesting 
that activating 5-HT3 receptors within the pVTA are involved in the expression of context-
induced EtOH-seeking behavior in P rats. 5-HT3 receptors play a role in increasing the 
activity of VTA DA neurons (Campbell et al. 1996). In addition, there are 5-HT3 receptors 
found within the pVTA (Herve et al. 1987). Inhibition of 5-HT3 receptors within the VTA 
can inhibit EtOH-induced extracellular DA release in the VTA (Campbell et al. 1996). A 
previous study (Hauser et al. 2011) indicated that activation of DA neurons in the pVTA, but 
not the anterior VTA, mediates context-induced EtOH-seeking behavior of P rats. Overall, 
these results suggest that activation of 5-HT inputs at 5-HT3 receptors in the pVTA, 
resulting in the stimulation of VTA DA neurons, may be involved in the expression of 
EtOH-seeking behavior.
The current results are in agreement with the findings of Le et al. (2006b) who report that 
intraperitoneal injections of the 5-HT3 receptor antagonists, ondansetron and tropisetron, 
reduced footshock-induced EtOH-seeking behavior in Wistar rats. In addition, the current 
findings also support clinical findings that administration of a 5-HT3 receptor antagonist can 
reduce alcohol craving in alcohol-dependent subjects (Johnson 2004; Johnson et al. 2002; 
Sellers et al. 1994).
In contrast, other studies have found that the 5-HT3 receptor antagonist ondansetron did not 
alter nicotine-induced decreases in self-stimulation threshold within the VTA (Ivanova and 
Greenshaw 1997) nor did the 5-HT3 antagonists ICS 205–930 and MDL-72222 alter 
intravenous nicotine self-administration or nicotine-induced stimulation of activity 
(Corrigall and Coen 1994). The apparent disagreement between the present study and those 
mentioned above may be due to a combination of factors, including different mechanisms 
that may underlie the different behaviors that were measured, as well as differences in the 
drug histories of the animals and the routes of administration of the antagonists.
If activation of 5-HT3 receptors in the pVTA is involved in regulating context-induced 
EtOH-seeking behavior, as suggested by the results with zacopride (Fig. 6), then local 
microinfusion of a 5-HT3 receptor agonist into the pVTA should increase expression of 
context-induced EtOH-seeking behavior. The microinjection of 1 µM CPBG into the pVTA 
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increased responding on the EtOH lever approximately twofold over aCSF levels of 
responding (Fig. 7a), providing additional support for the involvement of 5-HT3 receptors in 
mediating context-induced EtOH-seeking behavior. This effect did not appear to be due to 
an increase in general motor activity since responses on the water lever were not altered 
(Fig. 7b). However, in contrast to the effects observed with 1 µM CPBG, the microinjection 
of 10 µM CPBG into the pVTA significantly reduced responding on the EtOH lever 
compared to aCSF levels (Fig. 7a). This concentration of CPBG should still be having an 
effect on DA release as suggested by reverse microdialysis studies (Campbell et al. 1996; 
Liu et al. 2006), and ICSA results showed that the 10 µM CPBG was the optimal 
concentration self-infused (Rodd et al. 2007). Therefore, it is possible that 10 µM effects of 
CPBG, due to its enhanced reinforcing effects and higher DA release in pVTA, are 
producing a euphoric effect leading to the reduction of context-induced EtOH seeking in the 
current study. Alternatively, it is possible that the current experimental approach may be 
producing a local higher-CPBG concentration than the ICSA and reverse microdialysis 
procedures, resulting in inhibition of DA reuptake and higher concentrations of DA-
activating D2 autoreceptors, which would reduce VTA DA neuronal activity and inhibit 
EtOH-seeking behavior (Hauser et al. 2011).
Varenicline, an α4β2 nACh receptor partial agonist and a potent 5-HT3 receptor agonist 
(Lummis et al. 2011), reduced EtOH-seeking behavior in rats (Steensland et al. 2007). The 
apparent differences between the current 5-HT3 agonist results and Steensland et al. (2007) 
findings may be due to differences in the route of administration, e.g., with systemic 
administration; varenicline may be acting at sites outside the VTA to reduce EtOH seeking.
Nicotinic receptors within the pVTA appear to be involved in mediating EtOH-seeking 
behavior. Microinfusion of 100 and 200 µM nicotine increased responding on the EtOH 
lever twofold over control values (Fig. 2a). These concentrations did not alter responding on 
the water lever (Fig. 2b), indicating that the increased responding on the EtOH lever was not 
due to an increase in general motor activity. Concentrations of 10 to 200 µM nicotine were 
self-infused into the pVTA by P rats (Hauser et al. 2013), suggesting that the concentrations 
of nicotine used in the present study can produce positive effects. Local application of 100 
µMnicotine within the VTA has been shown to increase somatodendritic (Rahman et al. 
2004) and terminal (Ding et al. 2012) DA release. Overall, the results are consistent with 
effects of nicotine on EtOH-seeking behavior being mediated by increased VTA DA 
neuronal activity. These results are in agreement with previous studies that demonstrated (a) 
the involvement of pVTA DA neuronal activity (Hauser et al. 2011) in regulating EtOH 
seeking and (b) that systemically administered nicotine significantly enhanced EtOH-
seeking behavior in P rats (Hauser et al. 2012a). The nicotine concentrations in the current 
study approximate levels attained by human smokers (15–150 ng/ml; Benowitz and Jacob 
1984) and of P rats consuming nicotine (Hauser et al. 2012b).
The enhancing effect of nicotine on EtOH-seeking behavior was inhibited by coinfusion 
with Mec (Fig. 4a) and Zac (Fig. 5a), suggesting that nicotine may be acting at both nACh 
and 5-HT3 receptors. These results are consistent with the effects of 5-HT3 receptor 
antagonists inhibiting the self-infusion of nicotine into the pVTA (Hauser et al. 2013), and 
with the high affinity of nicotine for the 5-HT3 receptor (Jackson and Yakel 1995). 
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Responding on the water lever was not altered by any of the treatments (Figs. 4b and 5b); 
because of the low responses on the water lever, a floor effect may have prevented 
observing any reduced responding due to general motor impairment. However, previous 
studies indicated that microinjection of a 5-HT3 receptor antagonist into the pVTA did not 
impair operant responding (Rodd et al. 2010); neither systemic (Ford et al. 2009) nor VTA 
(Ericson et al. 1998) administration of Mec appeared to impair motor activity. Interestingly, 
it has been reported that Mec (10 µM) can inhibit 5-HT-activated currents by acting as an 
antagonist at 5-HT3 receptors (Drisdel et al. 2008), thus suggesting that Mec may be a 5-
HT3 receptor antagonist as well as a nACh receptor antagonist in the current study on EtOH 
seeking. However, it is not clear if the results of the present study are selective for EtOH-
seeking behavior or if similar effects could also be observed for other drugs.
The α4 nicotinic receptor and 5-HT3 receptor coexist on striatal nerve terminals (Dougherty 
and Nichols 2009; Nayak et al. 2000), although it is not known if a similar coexistence also 
occurs within the VTA. Activation of nACh or 5-HT3 receptors within the pVTA produces 
reinforcing effects (Hauser et al. 2013; Rodd et al. 2007) and stimulates DA release (Liu et 
al. 2006; Rahman et al. 2004), suggesting that both types of receptors may be located on 
VTADA neurons. Antagonism of nACh receptors with Mec can reduce nicotine-induced 
DA release within VTA (Nisell et al. 1994; Rahman et al. 2004). Although there are no 
current reports on Zac’s effects on nicotine-induced DA release, it has been reported that the 
5-HT3 antagonist ICS 205–930 can attenuate systemic nicotine-induced DA release in the 
Acb, thus suggesting that some of nicotine’s stimulating effects on DA may be mediated in 
part by 5-HT3 receptors (Carboni et al. 1989). The α4 and α6 nicotinic receptors have been 
shown to be necessary for nicotine-induced DA neuronal activity in the VTA (Zhao-Shea et 
al. 2011; Gotti et al. 2010); α7 nicotinic receptors located on the presynaptic glutamate 
terminals (Albuquerque et al. 2009; Gotti and Clementi 2004; Nayak et al. 2000; Wonnacott 
1997) are thought to prolong DA neurotransmission by enhancing glutamatergic excitation 
in the presence of nicotine (Pidoplichko et al. 2004). 5-HT3 receptors also appear to be 
involved in mediating the release of glutamate (Dong et al. 2009). Overall, these latter 
findings suggest that the interactions of nicotinic and 5-HT3 receptors within the pVTA are 
likely complex and involve more than just their interactions directly on DA neurons.
In conclusion, the ability of local applications of nicotine into the pVTA to promote context-
induced EtOH seeking suggests that the pVTA is a neuroanatomical site in which drugs of 
abuse can activate seeking behavior for another drug of abuse. The current findings also 
provide evidence that the actions of nicotine appear to occur through its effects at both 
nACh and 5-HT3 receptors in the pVTA and that activation of 5-HT3 receptors may play a 
role in mediating context-induced EtOH seeking.
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Fig. 1. 
Representative dual placements for the microinfusions of aCSF, nicotine, zacopride, or 
CPBG into pVTA of P rats are shown. Filled circles represent placements of injection sites 
within the pVTA (defined as −5.4 to −6.0 mm bregma)
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Fig. 2. 
Mean (±SEM) responses per session on the lever previously associated with the delivery of 
EtOH (a) or water (b) by P rats (n=6–7/group) microinjected with aCSF or 50, 100, or 200 
µM nicotine into the pVTA. Asterisk (*) indicates that rats that administered aCSF or 50, 
100, or 200 µM nicotine responded significantly (p<0.05) more on the EtOH lever during 
the first PSR session compared to extinction baseline levels. Double pound (##) indicates 
that 100 or 200 µM nicotine increased responding on the EtOH lever during the first PSR 
session compared to the aCSF and 50 µM nicotine (p<0.05)
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Fig. 3. 
Mean (±SEM) responses per session on the lever previously associated with the delivery of 
EtOH (a) or water (b) by P rats (n= 1–6/group), with placements in the anterior VTA and 
red nucleus, microinjected with aCSF or 50, 100, or 200 µM nicotine. No significant 
differences were detected
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Fig. 4. 
Mean (±SEM) responses per session on the lever previously associated with the delivery of 
EtOH (a) or water (b) by P rats (n=6–7/group) microinjected with aCSF or 100 µM nicotine, 
100 µM nicotine+ 100 µM mecamylamine (a nonselective nicotinic receptor antagonist), or 
100 µM nicotine+µM mecamylamine into the pVTA. Asterisk (*) indicates that rats that 
administered aCSF, 100 µM nicotine, or 100 µM nicotine+100 µM mecamylamine 
responded significantly (p<0.05) more on the EtOH lever during the first PSR session 
compared to extinction baseline levels. Double pound (##) indicates that 100 µM nicotine or 
100 µM nicotine+100 µM mecamylamine increased responding on the EtOH lever during 
the first PSR session compared to the aCSF, whereas 100 µM nicotine+200 µM 
mecamylamine decreased responding on the EtOH lever during the first PSR session 
compared to 100 µM nicotine or 100 µM nicotine+100 µM mecamylamine (p<0.05)
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Fig. 5. 
Mean (±SEM) responses per session on the lever previously associated with the delivery of 
EtOH (a) or water (b) by P rats (n=5–7/group) microinjected with aCSF, 100 µM nicotine, 
100 µM nicotine+ 100 µM zacopride (a 5-HT3 receptor antagonist), or 100 µM nicotine+ 
200 µM zacopride into the pVTA. Asterisk (*) indicates that rats that administered aCSF or 
100 µM nicotine responded significantly (p<0.05) more on the EtOH lever during the first 
PSR session compared to extinction baseline levels. Double pound (##) indicates that 100 
µM nicotine+100 µM zacopride, or 100 µM nicotine+200 µM zacopride decreased 
responding on the EtOH lever during the first PSR session compared to the aCSF or 100 µM 
nicotine (p<0.05)
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Fig. 6. 
Mean (±SEM) responses per session on the lever previously associated with the delivery of 
EtOH (a) or water (b) by P rats (n=5–8/group) microinjected with aCSF, or 100 or 200 µM 
zacopride (a 5-HT3 receptor antagonist) into the pVTA. Asterisk (*) indicates that rats that 
administered aCSF responded significantly (p<0.01) more on the EtOH lever during the first 
PSR session compared to extinction baseline levels. Double pound (##) indicates that 100 or 
200 µM zacopride significantly decreased responding on the EtOH lever during the first PSR 
session compared to aCSF (p<0.01)
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Fig. 7. 
Mean (±SEM) responses per session on the lever previously associated with the delivery of 
EtOH (a) or water (b) by P rats (n=4–5/group) microinjected with aCSF, or 1 or 10 µM 
CPBG (a 5-HT3 receptor agonist) into the pVTA. Asterisk (*) indicates that rats that 
administered aCSF or 1 µM CPBG responded significantly (p<0.05) more on the EtOH lever 
during the first PSR session compared to extinction baseline levels. Double pound (##) 
indicates that 1 µM CPBG increased responding on the EtOH lever, and 10 µM CPBG 
decreased responding on the EtOH lever during the first PSR session compared to the aCSF 
(p<0.01)
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Table 1
Representation of EtOH and water lever responses (mean± SEM) during the last 5 days of maintenance, the 
first day of extinction, and last 3 days of extinction that were used for baseline prior to the first PSR session
EtOH Lever (FR5) Water Lever (FR1) EtOH (g/kg)
Experiment 1 (Nicotine)
  EtOH Maintenance 202±22 10±2 1.4±0.2
  Extinction (Day 1) 146±11 10±2
  Base Extinction (last 3 days) 26±3 9±3
Experiment 2 (Nicotine+Mecamylamine)
  EtOH Maintenance 204±15 15±3 1.5±0.1
  Extinction (Day 1) 180±11 22±3
  Base Extinction (last 3 days) 29±3 13±2
Experiment 3 (Nicotine+Zacopride)
  EtOH Maintenance 182±15 19±3 1.3±0.1
  Extinction (Day 1) 144±11 8±4
  Base Extinction (last 3 days) 27±3 14±3
Experiment 4 (Zacopride)
  EtOH Maintenance 168±18 14±3 1.2±0.1
  Extinction (Day 1) 151±15 33±9
  Base Extinction (last 3 days) 31±6 17±4
Experiment 5(CPBG)
  EtOH Maintenance 218±19 9±2 1.5±0.1
  Extinction (Day 1) 147±10 12±2
  Base Extinction (last 3 days) 35±7 11±4
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